UroGen Pharma Ltd. (URGN) stock
Close on Nov 18, 2026Market cap $1.46BP/E –Yield –
Earnings
UroGen Pharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of UroGen Pharma's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 1, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026before the open | $89.00M | +223.6% | -$0.03 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026before the open | $51.00M | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 2, 2026before the open | $37.84M | +53.8% | -$0.54 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $27.50M | +9.1% | -$0.69 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | $24.20M | +11.0% | -$1.05 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 10, 2025before the open | $24.60M | +4.7% | -$0.80 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024before the open | $25.20M | +20.6% | -$0.55 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024before the open | $21.80M | +3.3% | -$0.91 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024before the open | $18.80M | +9.3% | -$0.97 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 14, 2024before the open | $23.50M | +29.8% | -$0.72 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023before the open | $20.90M | +29.8% | $0.68 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023before the open | $21.10M | +27.1% | -$1.03 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023before the open | $17.20M | +26.5% | -$1.30 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 22, 2023after the close | $18.10M | +11.7% | -$1.22 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | $16.10M | +41.2% | -$1.13 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022before the open | $16.60M | – | -$1.18 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022before the open | $13.60M | – | -$1.25 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 21, 2022before the open | $16.20M | – | -$1.27 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021before the open | $11.40M | – | -$1.35 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 14, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 18, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 9, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
UroGen Pharma's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| net product revenue for JELMYTO | FY2026 | $97.00M – $101.00M | $97.00M – $101.00M | Reaffirmed | Aug 5, 2026 |
| net product revenue guidance for JELMYTO | FY2026 | $90.00M | – | New | Nov 4, 2026 |
| year-over-year growth rate | FY2026 | +3% – +7% | +3% – +7% | Reaffirmed | Aug 5, 2026 |
| non-cash share-based compensation expense | FY2026 | $20.00M – $24.00M | – | Lowered | Nov 4, 2026 |
| non-cash share-based compensation expense | FY2026 | $20.00M – $24.00M | $20.00M – $24.00M | Lowered | Aug 5, 2026 |
| operating expenses | FY2026 | $260.00M – $270.00M | – | New | Nov 4, 2026 |
| operating expenses | FY2026 | $260.00M – $270.00M | $240.00M – $250.00M | Raised | Aug 5, 2026 |
Guidance history
Every forecast UroGen Pharma put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | operating expenses | FY2026 | $260.00M – $270.00M | New |
| Nov 4, 2026 | non-cash share-based compensation expense | FY2026 | $20.00M – $24.00M | Lowered |
| Nov 4, 2026 | net product revenue guidance for JELMYTO | FY2026 | $90.00M | New |
| Aug 5, 2026 | operating expenses | FY2026 | $260.00M – $270.00M | Raised |
| Aug 5, 2026 | non-cash share-based compensation expense | FY2026 | $20.00M – $24.00M | Lowered |
| Aug 5, 2026 | year-over-year growth rate | FY2026 | +3% – +7% | Reaffirmed |
| Aug 5, 2026 | net product revenue for JELMYTO | FY2026 | $97.00M – $101.00M | Reaffirmed |
| May 6, 2026 | operating expenses | FY2026 | $240.00M – $250.00M | Raised |
| May 6, 2026 | non-cash share-based compensation expense | FY2026 | $20.00M – $24.00M | Lowered |
| May 6, 2026 | year-over-year growth rate | FY2026 | +3% – +7% | Reaffirmed |
| May 6, 2026 | net product revenue for JELMYTO | FY2026 | $97.00M – $101.00M | Reaffirmed |
| Mar 2, 2026 | operating expenses | FY2026 | $240.00M – $250.00M | New |
| Mar 2, 2026 | non-cash share-based compensation expense | FY2026 | $20.00M – $24.00M | Lowered |
| Mar 2, 2026 | year-over-year growth rate | FY2026 | +3% – +7% | New |
| Mar 2, 2026 | net product sales for JELMYTO | FY2026 | $97.00M – $101.00M | New |
| Nov 6, 2025 | operating expenses | FY2025 | $215.00M – $225.00M | New |
| Nov 6, 2025 | non-cash share-based compensation expense | FY2025 | $11.00M – $14.00M | Lowered |
| Nov 6, 2025 | year-over-year growth rate | FY2025 | +8% – +12% | New |
| Nov 6, 2025 | net product revenues for JELMYTO | FY2025 | $94.00M – $98.00M | New |
| Aug 7, 2025 | operating expenses | FY2025 | $215.00M – $225.00M | Raised |
| Aug 7, 2025 | net product revenues for JELMYTO | FY2025 | $94.00M – $98.00M | Reaffirmed |
| May 12, 2025 | operating expenses | FY2025 | $215.00M – $225.00M | Raised |
| May 12, 2025 | non-cash share-based compensation expense | FY2025 | $11.00M – $14.00M | Lowered |
| May 12, 2025 | year-over-year growth rate | FY2025 | +8% – +12% | Reaffirmed |
| May 12, 2025 | net product revenues for JELMYTO | FY2025 | $94.00M – $98.00M | Reaffirmed |
| Mar 10, 2025 | operating expenses | FY2025 | $215.00M – $225.00M | New |
| Mar 10, 2025 | non-cash share-based compensation expense | FY2025 | $11.00M – $14.00M | Lowered |
| Mar 10, 2025 | year-over-year growth rate | FY2025 | +8% – +12% | New |
| Mar 10, 2025 | net product revenues from JELMYTO | FY2025 | $94.00M – $98.00M | New |
| Nov 6, 2024 | rate for the cash component of the RTW obligation | FY2024 | 13% | Reaffirmed |
| Nov 6, 2024 | non-cash share-based compensation expense | FY2024 | $9.00M – $13.00M | Lowered |
| Nov 6, 2024 | non-cash financing expense related to the prepaid obligation to RTW Investments | FY2024 | $21.00M – $26.00M | Raised |
| Aug 13, 2024 | rate for the cash component of the RTW obligation | FY2024 | 13% | New |
| Aug 13, 2024 | revised non-cash share-based compensation expense | FY2024 | $9.00M – $13.00M | Lowered |
| Aug 13, 2024 | non-cash financing expense related to the prepaid obligation to RTW Investments | FY2024 | $21.00M – $26.00M | Raised |
| May 13, 2024 | operating expenses | FY2024 | $175.00M – $185.00M | Raised |
| May 13, 2024 | non-cash financing expense related to the prepaid obligation to RTW Investments | FY2024 | $21.00M – $26.00M | Lowered |
| May 13, 2024 | net product revenues | FY2024 | $95.00M – $102.00M | Reaffirmed |
| Mar 14, 2024 | operating expenses | FY2024 | $175.00M – $185.00M | New |
| Mar 14, 2024 | non-cash share-based compensation expense | FY2024 | $6.00M – $11.00M | Lowered |
| Mar 14, 2024 | non-cash financing expense related to the prepaid obligation to RTW Investments | FY2024 | $21.00M – $26.00M | Raised |
| Mar 14, 2024 | expected to be in cash | FY2024 | $12.40M – $13.30M | Lowered |
| Mar 14, 2024 | net product revenues from JELMYTO | FY2024 | $95.00M – $102.00M | New |
| Nov 14, 2023 | operating expenses | FY2023 | $135.00M – $145.00M | Raised |
| Nov 14, 2023 | non-cash financing expense related to the prepaid obligation to RTW Investments | FY2023 | $21.00M – $26.00M | Lowered |
| Nov 14, 2023 | net product revenues from JELMYTO | FY2023 | $76.00M – $86.00M | Reaffirmed |
| Aug 10, 2023 | operating expenses | FY2023 | $135.00M – $145.00M | Raised |
| Aug 10, 2023 | non-cash share-based compensation expense | FY2023 | $6.00M – $11.00M | Lowered |
| Aug 10, 2023 | non-cash financing expense related to the prepaid obligation to RTW Investments | FY2023 | $21.00M – $26.00M | Raised |
| Aug 10, 2023 | financing expense expected to be in cash | FY2023 | $9.90M – $11.20M | Lowered |
| Aug 10, 2023 | net product revenues from JELMYTO | FY2023 | $76.00M – $86.00M | Reaffirmed |
| May 11, 2023 | operating expenses | FY2023 | $135.00M – $145.00M | Raised |
| May 11, 2023 | non-cash financing expense related to the prepaid obligation to RTW Investments | FY2023 | $21.00M – $26.00M | Lowered |
| May 11, 2023 | net product revenues from JELMYTO | FY2023 | $76.00M – $86.00M | Reaffirmed |
| Mar 22, 2023 | operating expenses | FY2023 | $135.00M – $145.00M | New |
| Mar 22, 2023 | financing expense related to the prepaid obligation to RTW Investments | FY2023 | $21.00M – $26.00M | Lowered |
| Mar 22, 2023 | net product revenues from JELMYTO | FY2023 | $76.00M – $86.00M | New |
| Aug 11, 2022 | operating expenses | FY2022 | $130.00M – $140.00M | Raised |
| Aug 11, 2022 | non-cash share-based compensation expense | FY2022 | $10.00M – $16.00M | Lowered |
| Aug 11, 2022 | non-cash financing expense related to the prepaid obligation to RTW Investments | FY2022 | $22.00M – $26.00M | Raised |
| Aug 11, 2022 | paid in cash | FY2022 | $9.10M – $10.40M | Lowered |
| Aug 11, 2022 | net product revenues from Jelmyto | FY2022 | $70.00M – $80.00M | Reaffirmed |
| May 10, 2022 | operating expenses | FY2022 | $140.00M – $160.00M | Raised |
| May 10, 2022 | non-cash share-based compensation expense | FY2022 | $10.00M – $16.00M | Lowered |
| May 10, 2022 | non-cash financing expense related to the prepaid obligation to RTW Investments | FY2022 | $22.00M – $26.00M | Raised |
| May 10, 2022 | prepaid obligation to RTW Investments to be paid in cash | FY2022 | $9.10M – $10.40M | Lowered |
| May 10, 2022 | net product revenues from Jelmyto | FY2022 | $70.00M – $80.00M | Reaffirmed |
| Mar 21, 2022 | operating expenses | FY2022 | $140.00M – $160.00M | New |
| Mar 21, 2022 | financing expense related to the prepaid obligation to RTW Investments | FY2022 | $22.00M – $26.00M | Lowered |
| Mar 21, 2022 | net product revenues from Jelmyto | FY2022 | $70.00M – $80.00M | New |
| Nov 15, 2021 | operating expenses | FY2021 | $137.00M – $142.00M | New |
| Nov 15, 2021 | revenue | FY2021 | $47.00M – $51.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases UroGen Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- News
- News
- Update
- Results
See a number that looks wrong?